| Anacetrapib | cardiovascular prevention, in all type of patients | vs placebo | NS | - | - | NS | NS | NS | - | NS | - | - | - | - | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.38 [0.55 3.44] | p=1.00 | 0 | 1623 | 1 | DEFINE, | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 4.00 [0.45 35.91] | p=1.00 | 0 | 1623 | 1 | DEFINE, | | Non fatal stroke | 1.00 [0.29 3.47] | p=1.00 | 0 | 1623 | 1 | DEFINE, | | Non fatal MI | 0.67 [0.24 1.88] | p=1.00 | 0 | 1623 | 1 | DEFINE, | | stroke (fatal and non fatal) | no data | | cardiovascular events | 0.76 [0.40 1.47] | p=1.00 | 0 | 1623 | 1 | DEFINE, | | Carotid revascularization | no data | | Coronary revascularization | no data | | change in mean CIMT | no data | | change in maximum CIMT | no data | | cardiovascular events including revascularization | 0.83 [0.44 1.58] | p=1.00 | 0 | 1928 | 2 | DEFINE, REALIZE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| DEFINE, 2010 | anacetrapib 100mg fr 18 months | placebo | patients with coronary heart disease or at high risk for coronary heart disease | | REALIZE, 2015 | oral anacetrapib 100 mg for 52 weeks | placebo | patients aged 18-80 years with a genotype-confirmed or clinical diagnosis of heterozygous familial hypercholesterolaemia, on optimum lipid-lowering treatment for at least 6 weeks, and with an LDL-C concentration of 2·59 mmol/L or higher without cardiovascular disease or 1·81 mmol/L or higher with cardiovascular disease |
|
| Torcetrapib | cardiovascular prevention, in all type of patients | vs placebo | by 53% | NS | NS | NS | NS | NS | NS | NS | - | by 25% | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.53 [1.12 2.09] | p=0.04 | 0 | 17159 | 3 | RADIANCE 1, ILLUMINATE, ILLUSTRATE, | | Coronary death | 1.21 [0.76 1.90] | p=1.00 | 0 | 16255 | 2 | ILLUMINATE, ILLUSTRATE, | | Coronary event | 1.22 [0.98 1.52] | p=1.00 | 0 | 15067 | 1 | ILLUMINATE, | | Cardiovascular death | 1.36 [0.89 2.10] | p=1.00 | 0 | 15971 | 2 | RADIANCE 1, ILLUMINATE, | | Non fatal stroke | 1.01 [0.06 16.18] | p=1.00 | 0 | 904 | 1 | RADIANCE 1, | | Non fatal MI | 1.17 [0.93 1.48] | p=1.00 | 0 | 17159 | 3 | RADIANCE 1, ILLUMINATE, ILLUSTRATE, | | stroke (fatal and non fatal) | 0.97 [0.64 1.47] | p=1.00 | 0 | 16255 | 2 | ILLUMINATE, ILLUSTRATE, | | cardiovascular events | 1.16 [0.95 1.41] | p=1.00 | 0 | 15067 | 1 | ILLUMINATE, | | Carotid revascularization | no data | | Coronary revascularization | 1.25 [1.10 1.41] | p=0.04 | 0 | 16255 | 2 | ILLUMINATE, ILLUSTRATE, | | change in mean CIMT | no data | | change in maximum CIMT | no data | | cardiovascular events including revascularization | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| RADIANCE 1, 2007 | atorvastatin combined with 60 mg of torcetrapib | atorvastatin monotherapy | patients with heterozygous familial hypercholesterolemia | | ILLUMINATE, 2007 | torcetrapib 60mg daily plus atorvastatin (at a dose established during the runinperiod) | atorvastatin alone | patients at highcardiovascular risk | | RADIANCE 2, 2007 | torcetrapib 60mg daily (on top of atorvastatin attitrated dose) | placebo +atorvastatin attitrated dose | patients with mixed dyslipidaemia | | ILLUSTRATE, 2007 | atorvastatin plus 60 mg of torcetrapib daily | atorvastatin monotherapy | patients with coronary disease |
|
